-
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
Friday, May 31, 2019 - 1:45pm | 1570Read More...The FDA approval machinery worked overtime in May, with several new labelings, original approvals and new molecule approvals coming through in the month. The month saw the approval of two new molecular entities, or NMEs: Novartis AG (NYSE: NVS)'s Piqray in combination with fulvestrant to treat...
-
Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates
Monday, March 4, 2019 - 12:50pm | 1831Read More...Biotech stocks had a fairly decent outing in February, with the iShares NASDAQ Biotechnology Index (NASDAQ: IBB) adding roughly 2.7 percent for the month compared to the 3 percent gain for the S&P 500 Index. After the government shutdown-related slackness in January, FDA review picked up in...
-
Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates
Wednesday, September 26, 2018 - 4:41pm | 1653Read More...September had several clinical trial results announcements and a few FDA approvals triggering moves in the space. New molecular moiety, or NME, approvals totalled a mere three in September, taking the total NME approvals for 2018 to 37 compared to 46 in 2017. Here are the PDUFA catalysts for...
-
Canaccord Slices Regeneron Price Target 32% On Eylea, Dupixent Challenges
Wednesday, February 21, 2018 - 12:07pm | 379Read More...Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares fell 31 percent over the last six months, and the company's headwinds appear unending. The biotech firm lost an advocate Wednesday on the basis of a rough outlook for Eylea and Dupixent treatments. The Rating Canaccord Genuity analyst John...
-
Expectations For Regeneron No Longer Realistic; Analyst Downgrades
Tuesday, August 1, 2017 - 9:58am | 334Read More...Analysts at Baird Equity Research turned bearish on Regeneron Pharmaceuticals Inc (NASDAQ: REGN) as investor expectation for a recently launched drug may be too high. The firm's Brian Skorney downgrades Regeneron's stock rating from Neutral to Underperform with an unchanged $408 price target....
-
Is It Time To Step To The Sidelines On Regeneron?
Monday, June 26, 2017 - 1:27pm | 400Read More...Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares have been on an uptrend since late April, adding roughly 40 percent. The run up has led to worries over whether the stock has gotten ahead of fundamentals. Bernstein downgraded Regeneron, citing a more balanced risk-reward scenario. The firm...
-
Regeneron's Dupixent Passes The FDA Muster; Baird Sees Strong Launch
Tuesday, March 28, 2017 - 12:41pm | 780Read More...Atopic dermatitis treatment candidate Dupixent jointly developed by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR)(NYSE: SNY) has scaled the regulatory hurdle, a day ahead of the scheduled FDA examination day. The companies said the FDA has okayed Dupixent Injection, the first...
-
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
Monday, March 20, 2017 - 9:17am | 1119Read More...In its biopharma catalysts tracker released March 1, Leerink termed the year 2017 as a busy one for Neuro and Oncology. The firm highlighted the important catalysts for 2017. Celgene — Multiple Readout In 2017 On Celgene Corporation (NASDAQ: CELG), the firm noted that it has multiple readouts...
